How can the supplier/buyer relationship evolve?
Industry urges FDA to take another stab at NDI draft guidance.
Victory is back in the hands of the FTC after a judge ruled in November that Lane Labs did violate its consent decree.
Dan Fabricant, PhD, director of FDA’s division of dietary supplement programs, took audience questions about FDA’s new dietary ingredient (NDI) draft guidance during a December webcast. As expected, the most popular question asked was how long FDA expects it will take to finish reviewing the draft guidance comments it received. Fabricant’s answer? “How do you eat an elephant? One bite at a time.”
It’s always a pleasure when FDA provides its GMP regulatory compliance updates. I’ve heard Brad Williams, manager of FDA’s Division of Dietary Supplement Programs, speak several times at industry events and, most recently, at October’s SupplySide West show in Las Vegas. Hearing firsthand from FDA how our industry is doing in terms of GMP compliance provides a good idea of where we are—and how far we have to go.
While glucosamine and chondroitin still lead the pack, the door may be open to other ingredients, each taking a different approach to joint health.
Does the form of omega-3 make a difference when it comes to bioavailability—and will more science be dedicated to elucidating the differences?
Through innovation centers, ingredient suppliers and brand marketers are working together to take product advancement to new heights.
Much has been written about the Food Safety Modernization Act and how it expands FDA power to recall or detain products suspected of contamination.